Dr. Wallace has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers Squibb and Genentech (less than $10,000 each) and research grants from Amgen and Pfizer.
Article first published online: 25 MAY 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 6, pages 2012–2021, June 2012
How to Cite
Wallace, C. A., Giannini, E. H., Spalding, S. J., Hashkes, P. J., O'Neil, K. M., Zeft, A. S., Szer, I. S., Ringold, S., Brunner, H. I., Schanberg, L. E., Sundel, R. P., Milojevic, D., Punaro, M. G., Chira, P., Gottlieb, B. S., Higgins, G. C., Ilowite, N. T., Kimura, Y., Hamilton, S., Johnson, A., Huang, B., Lovell, D. J. and for the Childhood Arthritis and Rheumatology Research Alliance (2012), Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis & Rheumatism, 64: 2012–2021. doi: 10.1002/art.34343
ClinicalTrials.gov identifier: NCT00443430.
The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health.
- Issue published online: 25 MAY 2012
- Article first published online: 25 MAY 2012
- Accepted manuscript online: 19 DEC 2011 10:58AM EST
- Manuscript Accepted: 13 DEC 2011
- Manuscript Received: 22 JUL 2011
- NIH. Grant Numbers: 1R21-AR-48355-1, 1RO1-AR-049762-01A2, 3R01-AR-049762-04S1, P60-AR-047784-07, P30-AR-47363
- Howe Endowment for Juvenile Rheumatoid Arthritis Research, Friends of the Childhood Arthritis and Rheumatology Research Alliance
- Arthritis Foundation
- Clinical and Translational Science Awards. Grant Numbers: UL1-RR-025014, UL1-RR-025764, UL1-RR-024131, CO6-RR-11234, UL1-RR-025750, KL2-RR-025749, TL1-RR-025748
- National Center for Research Resources
- NIH Roadmap for Medical Research
To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)–positive or RF-negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months.
Between May 2007 and October 2010, a multicenter, prospective, randomized, double-blind, placebo-controlled trial of 2 aggressive treatments was conducted in 85 children ages 2–16 years with polyarticular JIA of <12 months' duration. Patients received either methotrexate (MTX) 0.5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2). The primary outcome measure was clinical inactive disease at 6 months. An exploratory phase determined the rate of clinical remission on medication (6 months of continuous clinical inactive disease) at 12 months.
By 6 months, clinical inactive disease had been achieved in 17 (40%) of 42 patients in arm 1 and 10 (23%) of 43 patients in arm 2 (χ2 = 2.91, P = 0.088). After 12 months, clinical remission on medication was achieved in 9 patients in arm 1 and 3 patients in arm 2 (P = 0.053). There were no significant interarm differences in adverse events.
Although this study did not meet its primary end point, early aggressive therapy in this cohort of children with recent-onset polyarticular JIA resulted in clinical inactive disease by 6 months and clinical remission on medication within 12 months of treatment in substantial proportions of patients in both arms.